share_log

Avalo Therapeutics | 8-K: Current report

Avalo Therapeutics | 8-K: Current report

Avalo Therapeutics | 8-K:重大事件
美股sec公告 ·  05/23 16:07
Moomoo AI 已提取核心訊息
On May 20, 2024, Avalo Therapeutics, Inc. received a notice from the Nasdaq Listing Qualifications Department indicating that the company does not meet the Nasdaq Capital Market's continued listing requirement of maintaining a minimum of $2,500,000 in stockholders' equity. The notice was issued following Avalo Therapeutics' report of negative $112.6 million in stockholders' equity for the quarter ended March 31, 2024. The company has been given 45 days, until July 5, 2024, to submit a plan to regain compliance. If the plan is accepted, Nasdaq may grant up to 180 days for the company to demonstrate compliance. Avalo Therapeutics' common stock will continue to trade on the Nasdaq under the symbol 'AVTX' during this period. The company is exploring options to regain compliance, but there is no guarantee that...Show More
On May 20, 2024, Avalo Therapeutics, Inc. received a notice from the Nasdaq Listing Qualifications Department indicating that the company does not meet the Nasdaq Capital Market's continued listing requirement of maintaining a minimum of $2,500,000 in stockholders' equity. The notice was issued following Avalo Therapeutics' report of negative $112.6 million in stockholders' equity for the quarter ended March 31, 2024. The company has been given 45 days, until July 5, 2024, to submit a plan to regain compliance. If the plan is accepted, Nasdaq may grant up to 180 days for the company to demonstrate compliance. Avalo Therapeutics' common stock will continue to trade on the Nasdaq under the symbol 'AVTX' during this period. The company is exploring options to regain compliance, but there is no guarantee that the Nasdaq will accept its plan or that compliance will be achieved within any granted extension period. Failure to regain compliance could lead to a delisting determination, although the company would have the right to request a hearing before a Nasdaq Hearings Panel to present its compliance plan and request an additional extension.
2024年5月20日,Avalo Therapeutics, Inc.收到納斯達克上市資格部門的通知,表明該公司不符合納斯達克資本市場關於維持至少250萬美元股東權益的持續上市要求。該通知是在Avalo Therapeutics報告截至2024年3月31日的季度股東權益爲負1.126億美元之後發佈的。在2024年7月5日之前,該公司有45天的時間提交恢復合規的計劃。如果該計劃被接受,納斯達克可能會給予公司長達180天的時間來證明其合規性。在此期間,Avalo Therapeutics的普通股將繼續在納斯達克上市,股票代碼爲 “AVTX”。該公司正在探索恢復合規性的備選方案,但無法保證納斯達克會接受其計劃,也無法保證在任何允許的延期內實現合規。未能恢復合規性可能會導致退市決定,儘管該公司有權要求納斯達克聽證會小組舉行聽證會,以提交其合規計劃並要求進一步延期。
2024年5月20日,Avalo Therapeutics, Inc.收到納斯達克上市資格部門的通知,表明該公司不符合納斯達克資本市場關於維持至少250萬美元股東權益的持續上市要求。該通知是在Avalo Therapeutics報告截至2024年3月31日的季度股東權益爲負1.126億美元之後發佈的。在2024年7月5日之前,該公司有45天的時間提交恢復合規的計劃。如果該計劃被接受,納斯達克可能會給予公司長達180天的時間來證明其合規性。在此期間,Avalo Therapeutics的普通股將繼續在納斯達克上市,股票代碼爲 “AVTX”。該公司正在探索恢復合規性的備選方案,但無法保證納斯達克會接受其計劃,也無法保證在任何允許的延期內實現合規。未能恢復合規性可能會導致退市決定,儘管該公司有權要求納斯達克聽證會小組舉行聽證會,以提交其合規計劃並要求進一步延期。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息